Hormonal
SGLT2 inhibitors reduce the risk of hospitalization for heart failure and all-cause mortality in patients with type 2 diabetes compared to DPP-4 inhibitors.
If you have type 2 diabetes, ask your doctor about SGLT2 inhibitors (like empagliflozin). They are proven to lower the risk of heart failure hospitalization and death more effectively than DPP-4 inhibitors, offering significant cardiovascular protection beyond just blood sugar control.
initiation of empagliflozin treatment in real-world clinical settings was associated with a reduced risk of each of the outcomes of hospitalization for heart failure and all-cause mortality in comparison with DPP-4 inhibitors
Why this rating
Based on real-world administrative database studies and post-hoc analyses (EMPRISE East Asia), which are robust but observational compared to RCTs.
Source
Interplay of cardiovascular health and diabetes: Insights into weight management and risk reduction
Chih‐Yao Hsu et al. · Journal of Diabetes Investigation · 2024
DOI 10.1111/jdi.14164
More from this paper
- Sustained weight loss of at least 10% in the first year significantly reduces the incidence of cardiovascular disease in individuals with type 2 diabetes, whereas weight fluctuation without sustained loss increases risk.Good
- Maternal obesity during the first trimester of pregnancy increases the risk of congenital heart defects and cardiovascular issues in offspring, mediated in part by maternal pregestational diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →